AHA announces late-breaker lineup to be presented at 2023 Scientific Sessions

Key takeaways:

• The AHA announced the lineup of eight late-breaking sessions to be presented at its annual scientific sessions.
• The meeting will be held live in Philadelphia and virtually Nov. 10 to 13.

The American Heart Association Scientific Sessions, which will be held live in Philadelphia and can be attended virtually Nov. 10 to 13, will feature eight late-breaking science sessions over 3 days.

The AHA announced the following late-breaking science lineup for the annual meeting.

Late-Breaking Science 1: Obesity – Novel Therapeutics and Implications for Population Health:

• semaglutide (Wegovy, Novo Nordisk) and CV outcomes in patients with overweight or obesity and no diabetes: the SELECT trial

Late-Breaking Science 2: Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome:

• restrictive compared with liberal blood transfusion in patients with MI and anemia: the MINT trial;
• a randomized, placebo-controlled trial of PCI for stable angina: the ORBITA-2 trial; and
• a registry-based randomized trial of dapagliflozin (Farxiga, AstraZeneca) in patients with acute MI without diabetes: the DAPA-MI trial.

Late-Breaking Science 3: Heart Failure – VADS, Kids and Money:

• avoidance of aspirin with left ventricular assist devices in advanced heart failure: the ARIES HM3 trial;
• everolimus to prevent rejection in children after cardiac transplantation: the TEAMMATE trial; and
• a trial providing out-of-pocket costs for HF medications during clinical encounters.

Late-Breaking Science 4: Using Drugs, Diet and Delivery to Optimize Hypertension Outcomes —

• a randomized order crossover trial to evaluate the effects of dietary sodium on systolic BP in middle-aged adults: the CARDIA-SSBP trial;
• long-term BP control after physician optimized postpartum BP self-management: the POP-HT trial;
• a phase 2 study testing sustained BP reduction with the RNA interference therapeutic zilebesiran (Alnylam): the KARDIA-1 trial; and
• effectiveness of a BP-lowering intervention on risk for dementia among patients with hypertension: the CRHCP trial

Late-Breaking Science 5: Shocking Decisions in AFib Care —

• efficacy and safety of dual direct current cardioversion compared with single direct current cardioversion as a first-line treatment in patients with obesity and atrial fibrillation;
• a novel factor XI/XIa Inhibitor, abelacimab (Anthos Therapeutics) compared with rivaroxaban (Xarelto, Janssen/Bayer) in patients with AF: the AZALEA-TIMI 71 trial;
• efficacy and safety of edoxaban (Savaysa, Daiichi Sankyo) in patients with atrial high‐rate episodes lasting 24 hours or more: the NOAH-AFNET 6 trial; and
• apixaban (Eliquis, Bristol Myers Squibb/Pfizer) for the prevention of stroke in patients with subclinical AF: the ARTESIA trial.

Late-Breaking Science 6: Future of Lipid-Lowering Therapy — Novel Mechanisms and Approaches:

• effects of pitavastatin on CAD and inflammatory biomarkers in patients with HIV: a mechanistic substudy of the REPRIEVE trial;
• 一个多中心、随机、双盲、placebo-controlled phase 3 trial of recaticimab (Jiangsu Hengrui Medicine Co.) as add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia: the REMAIN-2 trial;
• a trial assessing the efficacy and safety of the extended duration short-interfering RNA lepodisiran (Eli Lilly), targeting lipoprotein (a); and
• a trial evaluating the safety and pharmacodynamic effects of Verve-101 (Verve Therapeutics), a DNA base editing medicine to durably inactivate the PCSK9 gene and reduce LDL cholesterol: the interim results of the phase 1b heart-1 trial.

Late-Breaking Science 7: From Local to Global: Achieving Equity in Prevention:

• the early results of a type 2 hybrid effectiveness and implementation interrupted time series trial of hypertension treatment in Nigeria: the HTN Program;
• a cluster randomized trial evaluating automated referral to centralized pharmacy services for evidence-based statin initiation for high-risk patients;
• the effect of intensive BP lowering in reducing risk for CV events: the ESPIRIT trial; and
• a cluster randomized trial evaluating the effect of a multifaceted implementation strategy on BP control among patients with low-income: the IMPACTS trial

Late-Breaking Science 8: Artificial Intelligence at the Bedside —

• a randomized clinical trial of peripartum cardiomyopathy screening using an AI-enhanced digital stethoscope: the SPEC-AI trial;
• novel AI to improve risk stratification of patients without obstructive CAD undergoing coronary CT angiography: the ORFAN trial;
• the validation of a speech analysis application to detect worsening HF events in ambulatory patients with HF; and
• a pragmatic randomized controlled trial assessing AI-enabled rapid identification of STEMI on ECG: the ARISE trial.

Healio | Cardiology Today will be on-site in Philadelphia to report the latest news from the AHA Scientific Sessions, with physician perspective, researcher interviews and more. Follow our breaking updateshereand by following @CardiologyToday on X (Twitter).